Updated

Revolution Medicines announced clinical trial results described as potentially signaling a paradigm shift in its therapeutic area, according to a Yahoo Finance report. The data drew investor attention as a possible catalyst for the biotech company's pipeline. The results add to a string of closely watched clinical readouts in the oncology and precision-medicine space, where investors are parsing early-stage data for signs of differentiated efficacy. Further details on trial design and endpoints were not immediately elaborated in initial coverage.